RS20050420A - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
RS20050420A
RS20050420A YUP-2005/0420A YUP20050420A RS20050420A RS 20050420 A RS20050420 A RS 20050420A YU P20050420 A YUP20050420 A YU P20050420A RS 20050420 A RS20050420 A RS 20050420A
Authority
RS
Serbia
Prior art keywords
inhibitor
disease
alzheimer
prevention
treatment
Prior art date
Application number
YUP-2005/0420A
Other languages
English (en)
Serbian (sr)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert HEUER
Hans Ludwig Schaefer
Original Assignee
Aventis Pharma S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A., filed Critical Aventis Pharma S.A.,
Publication of RS20050420A publication Critical patent/RS20050420A/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
YUP-2005/0420A 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease RS20050420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
RS20050420A true RS20050420A (en) 2007-04-10

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0420A RS20050420A (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (lt)
JP (1) JP2006514063A (lt)
KR (1) KR20050084250A (lt)
CN (1) CN1726016A (lt)
AR (1) AR042354A1 (lt)
AU (1) AU2003296802A1 (lt)
BR (1) BR0317280A (lt)
CA (1) CA2507945A1 (lt)
CO (1) CO5700712A2 (lt)
FR (1) FR2848452B1 (lt)
HR (1) HRP20050534A2 (lt)
MA (1) MA27500A1 (lt)
MX (1) MXPA05005556A (lt)
NO (1) NO20053341L (lt)
NZ (1) NZ540496A (lt)
PE (1) PE20040770A1 (lt)
PL (1) PL377110A1 (lt)
RS (1) RS20050420A (lt)
RU (1) RU2005121909A (lt)
TW (1) TW200503707A (lt)
WO (1) WO2004062652A1 (lt)
ZA (1) ZA200504656B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PL2157973T3 (pl) * 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
MX363161B (es) * 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
US20140243281A1 (en) * 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JP2001508762A (ja) * 1996-06-27 2001-07-03 ジー.ディー.サール アンド カンパニー 架橋した外殻領域および内部芯領域を有する両親媒性コポリマーからなり、医薬およびその他の用途に有用な粒子
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ES2257824T3 (es) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
PE20040770A1 (es) 2004-12-10
HRP20050534A2 (en) 2006-11-30
FR2848452A1 (fr) 2004-06-18
CO5700712A2 (es) 2006-11-30
BR0317280A (pt) 2005-11-08
CA2507945A1 (fr) 2004-07-29
NO20053341D0 (no) 2005-07-08
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
NO20053341L (no) 2005-09-07
MXPA05005556A (es) 2005-07-26
JP2006514063A (ja) 2006-04-27
NZ540496A (en) 2008-04-30
FR2848452B1 (fr) 2007-04-06
RU2005121909A (ru) 2006-01-20
PL377110A1 (pl) 2006-01-23
ZA200504656B (en) 2006-08-30
WO2004062652A1 (fr) 2004-07-29
TW200503707A (en) 2005-02-01
CN1726016A (zh) 2006-01-25
KR20050084250A (ko) 2005-08-26
AU2003296802A1 (en) 2004-08-10
EP1572174A1 (fr) 2005-09-14

Similar Documents

Publication Publication Date Title
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
GB0223040D0 (en) Therapeutic compounds
MXPA01006472A (es) Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
MY121399A (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
ZA200410011B (en) Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
HK1073313A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AP2004002951A0 (en) "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
PL377344A1 (pl) Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
IL174536A0 (en) Therapeutic treatment
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
NO20053341L (no) Hindring og behandling av Alzheimers sykdom.
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
TW200635900A (en) Chemical compound and its use
TW200714280A (en) Novel method of treating hyperlipidemia
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
WO2004080450A3 (en) Combined use of a fibrate and orlistat for the treatment of obesity
UA85187C2 (en) 2-aminobenzoyl derivatives